Korro Bio, Inc.

NASDAQ:KRRO

Biotechnology

Healthcare
$12.44 +15.88%

+$1.76 today

Market cap
$170.75M
Beta
2.10
P/E (TTM)
-1.3
EPS (TTM)
-$9.79
52W Low $5.20High $55.89

Volume 0.16M

Average 0.15M

KRRO Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Korro Bio, Inc.NASDAQ: KRRO

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 55.6% from a year ago

Common stock stood at $14K at the end of Q1 FY2026, up 55.6% from a year earlier and up 55.6% from the prior quarter.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +55.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14K+55.6% QoQ
Last fiscal yearDec 2025
$9K+0.0% YoY
Year agoMar 2025
$9K+55.6% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+55.6%——
1 year+0.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
9K USD
Year-over-year change
+0.0%
4-year CAGR
-28.8%

Common Stock vs competitors

How KRRO compares with its peers on the latest reported figures

  • KRRO's Mar 2026 common stock of $14K is the 7th highest of the 11 companies compared; the peer median is $132.5K.
  • Its year-over-year change of +55.6% is the 6th highest of 10, against a peer median of +60.9%.
  • Common stock amounts to 0.0% of total assets for KRRO, versus a peer median of 0.1%.
KRRO Competitors Peer median
Common Stock for KRRO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ENGNenGene Holdings Inc.Apr 2026$632M +23.9%+57.4%205.5%
AMRNAmarin Corporation plcMar 2026$314.06M +1.9%+1.2%48.6%
DBVTDBV Technologies S.A.Mar 2026$34M +191.8%+34.5%12.8%
SLNSilence Therapeutics plcMar 2026$10.29M +200.0%+24.1%8.9%
ANNXAnnexon, Inc.Mar 2026$162K +48.6%+45.9%0.1%
LRMRLarimar Therapeutics, Inc.Mar 2026$103K +60.9%+24.5%0.0%
KRROKorro Bio, Inc.Mar 2026$14K +55.6%—0.0%
ALTAltimmune, Inc.Mar 2026$13K +62.5%+30.1%0.0%
LBRXLB Pharmaceuticals Inc Common StockMar 2026$3K +200.0%+44.2%0.0%
ANROAlto Neuroscience, Inc.Mar 2026$3K +0.0%+44.2%0.0%
AURAAura Biosciences, Inc.Mar 2026$0 ——0.0%
Peer median (excluding KRRO) $132.5K+60.9%+34.5%0.1%

Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents79.64M36.94M166.15M55.64M21.82M
Short-term Investments51.07M18.92M070.45M53.33M
Net Receivables144K001.7M969K
Inventory00000
Other Current Assets1.04M(376K)3.56M3.74M6.25M
Total Current Assets134.75M57.08M172.73M131.53M82.37M
Property, Plant & Equipment (Net)36.87M11.89M42.82M51.55M16.22M
Goodwill00000
Intangible Assets00000
Long-term Investments13.42M4.54M3.41M36.96M12.44M
Tax Assets00002.2M
Other Non-current Assets320K228K2.71M6.2M270K
Total Non-current Assets50.61M16.66M48.94M94.71M31.13M
Total Assets185.36M73.74M221.66M226.24M113.51M
Account Payables2.75M2.61M7.28M3.99M1.65M
Short-term Debt2.58M2.92M000
Tax Payables00000
Deferred Revenue0003.51M7.84M
Other Current Liabilities1.73M551K395K4.05M(3.72M)
Total Current Liabilities11.43M8.7M19.48M14.96M11.94M
Long-term Debt14.17M163.86M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0005.91M7.84M
Other Non-current Liabilities87K163.86M1.05M1.47M1.48M
Total Non-current Liabilities43.11M164.07M32.27M50.87M50.13M
Total Liabilities54.53M172.77M51.75M65.83M62.07M
Common Stock35K08K9K9K
Retained Earnings(180.09M)(101.83M)(183.01M)(266.59M)(383.85M)
Accumulated OCI(62K)(5K)(0)268K212K
Other Stockholders Equity00000
Minority Interest00000
Total Equity130.82M(99.03M)169.91M160.42M51.44M
Total Debt45.6M166.99M33.21M44.77M43.49M
Net Debt(34.04M)130.06M(132.94M)(10.88M)21.66M

Korro Bio, Inc.

NASDAQ:KRRO

Intrinsic Alpha fair value

Locked

Current Price

$12.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.